tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NTLA Stock Latest News

Intellia Therapeutics initiated with a Buy at JonesResearch
The FlyIntellia Therapeutics initiated with a Buy at JonesResearch
2d ago
NTLA
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
PremiumPress Releases
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
8d ago
NTLA
Intellia Therapeutics price target lowered to $64 from $80 at Stifel
PremiumThe Fly
Intellia Therapeutics price target lowered to $64 from $80 at Stifel
9d ago
BEAM
KRYS
Krystal Biotech price target raised to $220 from $204 at Stifel
PremiumThe Fly
Krystal Biotech price target raised to $220 from $204 at Stifel
9d ago
BEAM
KRYS
Beam Therapeutics price target raised to $69 from $66 at Stifel
PremiumThe Fly
Beam Therapeutics price target raised to $69 from $66 at Stifel
9d ago
BEAM
KRYS
Cathie Wood’s ARK Investment bought 186K shares of Intellia Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment bought 186K shares of Intellia Therapeutics today
16d ago
NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16d ago
NTLA
Cathie Wood’s ARK Investment bought 237K shares of Intellia Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment bought 237K shares of Intellia Therapeutics today
1M ago
NTLA
Cathie Wood’s ARK Investment bought 119K shares of Intellia Therapeutics today
PremiumThe Fly
Cathie Wood’s ARK Investment bought 119K shares of Intellia Therapeutics today
1M ago
NTLA
Intellia Therapeutics price target raised to $90 from $73 at Canaccord
PremiumThe Fly
Intellia Therapeutics price target raised to $90 from $73 at Canaccord
1M ago
NTLA
Intellia Therapeutics price target lowered to $31 from $32 at Goldman Sachs
PremiumThe Fly
Intellia Therapeutics price target lowered to $31 from $32 at Goldman Sachs
1M ago
NTLA
Intellia Therapeutics price target lowered to $54 from $60 at RBC Capital
PremiumThe Fly
Intellia Therapeutics price target lowered to $54 from $60 at RBC Capital
1M ago
NTLA
Intellia Therapeutics sees cash runway into late 2026
PremiumThe FlyIntellia Therapeutics sees cash runway into late 2026
1M ago
NTLA
Intellia Therapeutics announces topline results from Phase study of NTLA-2002
Premium
The Fly
Intellia Therapeutics announces topline results from Phase study of NTLA-2002
1M ago
NTLA
Intellia Therapeutics reports Q2 EPS ($1.52), consensus ($1.23)
Premium
The Fly
Intellia Therapeutics reports Q2 EPS ($1.52), consensus ($1.23)
1M ago
NTLA
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
PremiumPress Releases
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
1M ago
NTLA
NTLA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
NTLA Upcoming Earnings Report: What to Expect?
1M ago
NTLA
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
PremiumPress Releases
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
2M ago
NTLA
Intellia receives authorization to initiate Phase 1/2 trial of NTLA-3001
PremiumThe Fly
Intellia receives authorization to initiate Phase 1/2 trial of NTLA-3001
2M ago
NTLA
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
PremiumPress ReleasesIntellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
2M ago
NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2M ago
NTLA
Cathie Wood’s ARK Investment bought 185K shares of Intellia Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment bought 185K shares of Intellia Therapeutics today
2M ago
NTLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >